Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.

  title={Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.},
  author={Jos Verweij and Marc Clavel and Beno{\^i}t Chevalier},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  volume={5 6},
Paclitaxel and docetaxel are the two presently clinically available representatives of the new class of taxane drugs. They share major parts of their structures and mechanisms of action, but differ in several other aspects. For instance, there is a difference in their tubulin polymer generation, and docetaxel appears twice as active in depolymerization inhibition. In vitro docetaxel also tends to be more potent in different cell lines and investigational models. While in vitro and in vivo… CONTINUE READING